Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Facon,Meletios-Athanasios Dimopoulos,Xavier P Leleu,Meral Beksac,Ludek Pour,Roman Hájek,Zhuogang Liu,Jiri Minarik,Philippe Moreau,Joanna Romejko-Jarosinska,Ivan Spicka,Vladimir I Vorobyev,Britta Besemer,Tadao Ishida,Wojciech Janowski,Sevgi Kalayoglu-Besisik,Gurdeep Parmar,Pawel Robak,Elena Zamagni,Hartmut Goldschmidt,Thomas G Martin,Salomon Manier,Mohamad Mohty,Corina Oprea,Marie-France Brégeault,Sandrine Macé,Christelle Berthou,David Bregman,Zandra Klippel,Robert Z Orlowski,IMROZ Study Group,Robert Orlowski,Tom Martin,Michele Cavo,Yvonne Dong,Raymond Comenzo,Gary Schiller,Juan Bautista Bladé Creixenti,James Neaton,Ross Baker,Kerry Taylor,Bradley Augustson,Silvia Ling,Jay Hocking,Michael Low,Jo Caers,Jie Jin,Lugui Qiu,Zhen Cai,Wei Li,Xinan Cen,Zhongjun Xia,Yu Hu,Hongmei Jing,Jianqing Mi,Xin Du,Jianda Hu,Xiaoyan Qu,Roman Hajek,Vladimir Maisnar,Alexandra Jungova,Pearl Van Heteren,Ivana Metzler,Henrik Gregersen,Niels Abildgaard,Anja Klostergaard,Xavier Leleu,Aurore Perrot,Julie Gay,Mourad Tiab,Jean-Noël Bastie,Cyrille Hulin,Pierre Feugier,Lionel Karlin,Margaret Macro,Sosana Delimpasi,Maria Papathanasiou,Sara Bringhen,Massimo Offidani,Alessandro Rambaldi,Alessandra Tucci,Takuya Komeno,Hiroyuki Fujita,Yuna Katsuoka,Kazutaka Sunami,Kentaro Yoshinaga,Shinsuke Iida,Takashi Ikeda,Satoshi Ito,Yawara Kawano,Valdas Peceliunas,Mindaugas Jurgutis,David Gomez Almaguer,Md Shahidul Islam,Sophie Leitch,Kirsty Marshall,Tadeusz Robak,Monika Szarejko,Tomasz Wozny,Fernando Leal da Costa,Angelo Martins,Luís Araújo,Herlander Marques,Fernanda Trigo,Vera Zherebtsova,Natalia Chernova,Jordi Lopez,Mercedes Gironella Mesa,Maria Jesus Blanchard Rodriguez,Felipe de Arriba de la Fuente,Johan Theander,Johan Lund,Sevgi Kalayoglu Besisik,Zubeyde Nur Ozkurt,Filiz Vural,Guner Hayri Ozsan,Ali Unal,Hakan Ozdogu,Su-Peng Yeh,Shang-Yi Huang,Kuan Ming Lai,Jesus Berdeja,James Reeves,David Wright
DOI: https://doi.org/10.1056/NEJMoa2400712
2024-10-31
Abstract:Background: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. Methods: In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. Results: A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P<0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P = 0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P = 0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. Conclusions: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, NCT03319667.).